Evaluation of time-dependent cytochrome P450 inhibition in a high-throughput, automated assay: Introducing a novel area under the curve shift approach

Drug Metabolism Letters

Volumn 6, Issue 1, 2012, Pages 43-53

  Mukadam, Sophie ^a   Tay, Suzanne ^a   Tran, Daniel ^a   Wang, Leslie ^a   Delarosa, Erlie M ^a   Khojasteh, S Cyrus ^a   Halladay, Jason S ^a   Kenny, Jane R ^a  

^a GENENTECH INC   (United States)

Author keywords

Automation; Cytochrome P450; Drug drug interactions; High throughput; In vitro; TDI AUC shift; TDI IC50 shift; Time dependent inhibition

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; MEPHENYTOIN; MIDAZOLAM; PHENACETIN; TESTOSTERONE; WARFARIN; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; AUTOMATION; DRUG ANTAGONISM; ENZYMOLOGY; IC 50; LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; TIME;

AREA UNDER CURVE; AUTOMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; NADP; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84863101646     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212800229309     Document Type: Article

References (23)

1. Borda, I. T.; Slone, D.; Jick, H. Assessment of adverse reactions within a drug surveillance program. JAMA, 1968, 205(9), 645-647.
2. Levy, M.; Kewitz, H.; Altwein, W.; Hillebrand, J.; Eliakim, M. Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur. J. Clin. Pharmacol., 1980, 17(1), 25-31.
3. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 2005, 4(10), 825-833.
4. Grimm, S.W.; Einolf, H.J.; Hall, S.D.; He, K.; Lim, H.K.; Ling, K.H.; Lu, C.; Nomeir, A.A.; Seibert, E.; Skordos, K.W.; Tonn, G.R.; Van Horn, R.; Want, R.W.; Wong, Y.N.; Yang, T.J.; Obach, R.S. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos., 2009, 37(7), 1355-70.
5. Silverman, R.B. Mechanism-based enzyme inactivators. Methods Enzymol., 1995, 249, 240-283.
6. Venkatakrishnan, K.; Obach, R.S.; Rostami-Hodjegan, A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica, 2007, 37(10-11), 1225-1256.
7. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J.C.; Clarke, S.E.; Lennard, M.S.; Tucker, G.T.; Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab., 2006, 7(3), 315-334.
8. Grime, K.H.; Bird, J.; Ferguson, D.; Riley, R.J. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur. J. Pharm. Sci., 2009, 36(2-3), 175-191.
9. Kohler, G. I.; Bode-Boger, S.M.; Busse, R.; Hoopmann, M.; Welte, T.; Boger, R.H. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther., 2000, 38(11), 504-513.
10. Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279(15), 1200-1205.
11. Kenny, J.R.; McGinnity, D.F.; Grime, K.; Riley, R.J. In: Handbook of Preclinical Drug Development; Gad, S.C.; John Wiley & Sons Inc, Hoboken, New Jersey, 2008; pp. 775-827.
12. Riley, R.J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition. Expert Opin. Drug Metab. Toxicol., 2007, 3(1), 51-66.
13. Dasgupta, M.; Tang, W.; Caldell, G.W.; Yan, Z. Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors. Rapid Commun. Mass Spectrom., 2010, 24(15), 2177-2185.
14. Mori, K.; Hashimoto, H.; Takatsu, H.; Tsuda-Tsukimoto, M.; Kume, T. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica, 2009, 39(6), 415-422.
15. Perloff, E.S.; Mason, A.K.; Dehal, S.S.; Blanchard, A.P.; Morgan, L.; Ho, T.; Dandeneau, A.; Crocker, R.M.; Chandler, C.M.; Boily, N.; Crespi, C.L.; Stresser, D.M. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica, 2009, 39(2), 99-112.
16. Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K. Risk assessment for drug-drug interaction caused by metabolismbased inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos., 2007, 35(7), 1232-1238.
17. Atkinson, A.; Kenny, J.R.; Grime, K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos., 2005, 33, 1637-1647.
18. Halladay, J.S.; Delarosa, E.M.; Tran, D.; Wang, L.; Wong, S.; Khojasteh, S.C. High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metab. Lett., 2011, 5(3), 220-230.
19. Obach, R.S., Walsky, R.L.; Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 2007, 35(2), 246-255.
20. Kajbaf, M.; Longhi, R.; Fontana, S. Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI). Drug Metab. Lett., 2011, 5(2), 104-113.
21. Miller, V. High-Throughput In Vitro ADME Analysis with Agilent RapidFire/MS Systems: Cytochrome P450 Inhibition. Application Note Available from: https://www.chem.agilent.com/en-US/Search/Library/Pages/LibrarySearchResults.aspx?a=Scope:%22Library+ Content%22+ContentType2:Application+ProductGroup:%22Mass+ Spectrometry%22+ProductType:%22RapidFire+High-throughput+ MS+Systems%22+Language:%22English+(U.S.)%22 (Accessed October 12, 2010)
22. Parkinson, A.; Kazmi, F.; Buckley, D.B.; Yerino, P.; Paris, B.L.; Holsapple, J.; Toren, P.; Otradovec, S.M.; Ogilvie, B.W. An evaluation of the dilution method for identifying metabolism dependent inhibitors of cytochrome p450 enzymes. Drug Metab. Dispos., 2011, 39(8), 1370-1387.
23. Rowland-Yeo K.; Jamei, M.; Yang, J.; Tucker, G.T.; Rostami-Hodjegan, A. Physiologically based mechanistic modeling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci., 2010, 39(5), 298-309.